All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-10-17T09:17:17.000Z

SLS009 granted orphan drug designation by the U.S. FDA

Oct 17, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new development in AML.

Bookmark this article

On October 10, 2023, the U.S. Food and Drug Administration granted orphan drug designation to SLS009 (formerly GFH009), a novel and highly selective CDK9 inhibitor, for the treatment of patients with acute myeloid leukemia (AML).1

The orphan drug designation is based on results from a phase I trial that showed SLS009 to be associated with:

  • 77.3% bone marrow blast reduction.1
  • Durable complete remission with no measurable residual disease.1
  • 24 hours >IC90 peripheral blood concentrations following the first infusion, with IC90 concentrations resulting in up to 97% of cancer cells being killed.1
  • Decrease in MCL1 and MYC in 97% of patients.1
  • No dose-limiting toxicities, no higher grade non-hematologic toxicities of any kind, and some treatable hematologic toxicities.1

SLS009 is currently being investigated in an open-label, single-arm, multi-center phase IIa trial (NCT04588922) to assess the safety, tolerability, and efficacy of SLS009 at two dose levels (once weekly at 45mg and 60mg) in combination with azacitidine and venetoclax in patients with relapsed/refractory AML.1

  1. SELLAS Life Sciences Group. SELLAS receives FDA orphan drug designation for SLS009 for treatment of acute myeloid leukemia. https://www.sellaslifesciences.com/investors/news/News-Details/2023/SELLAS-Receives-FDA-Orphan-Drug-Designation-for-SLS009-for-Treatment-of-Acute-Myeloid-Leukemia/default.aspx. Published Oct 10, 2023. Accessed Oct 12, 2023.

More about...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox